Dharwad News Today

Human Immunodeficiency Virus (HIV 1) Infection Pipeline, 2021

 Breaking News
  • No posts were found

Human Immunodeficiency Virus (HIV 1) Infection Pipeline, 2021

June 11
19:30 2021
Human Immunodeficiency Virus (HIV 1) Infection Pipeline, 2021

DelveInsight Business Research LLP
DelveInsight’s, “Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

What is Human Immunodeficiency Virus Type 1 (HIV-1) Infection?

HIV-1 is the most common type of Human Immunodeficiency Virus. It attacks the body’s immune system. The virus destroys CD4 cells. CD4 cells help the body to fight infections. HIV-1 can severely damage immune system and lead to Acquired Immune Deficiency Syndrome (AIDS). Infection with HIV type 1 (HIV-1) typically occurs across mucosal surfaces or by direct inoculation. The virus first encounters dendritic cells (DCs), which subsequently facilitate spread of HIV-1 to CD4+ T lymphocytes.

DelveInsight’s, “Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Which are the companies involved in developing Human Immunodeficiency Virus Type 1 Infection Pipeline drugs?

 

HIV-1 Infection Emerging Drugs

  • UB421: United BioPharma

UB-421 is an experimental HIV antibody, under development in phase III by United Biomedical, Inc. (UBI), headquartered in Hauppauge, New York, U.S. for use in the treatment of HIV infection. By blocking the CDR2 domain of the CD4 receptor of the virus, it prevents initial viral attachment to the host T cell and entry into the host immune cell via a competitive inhibition mechanism.

  • Islatravir (MK-8591): Merck Sharp & Dohme

Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors (NRTTIs). NRTTIs use several different methods to block an HIV enzyme called reverse transcriptase. By blocking reverse transcriptase, NRTTIs prevent HIV from multiplying and can reduce the amount of HIV in the body. Currently, it is being investigated in Phase III as a potential treatment for Hiv 1 infections.

  • PRO140: CytoDyn Inc.

Leronlimab (Pro 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated in Phase II as a potential treatment for HIV1 infections.

For more information, click here @ HIV-1 Infection Clinical Trials

Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/dharwadnewstoday.org/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share